Are multinational pharma firms justified in pricing life savings drugs exhorbitantly?
MNCs claim they spend billions and billions of dollars on research and development to make life saving drugs and that they are forced to charge exhorbitantly high prices in order to stay in business. The flip side of this argument is that such drugs are out of reach for the poor and that profit should not be the sole motive for being in the business of wellness, and that cheaper variants of the drug should be made available to the poor by other companies that have the technology to make them. What is your view? Are the MNCs justified or are they just interested in profits, working as they are in an industry where the consumer -- the patient -- has little choice?
MORE ON MARKETS:
Copyrights © 2017 Business Standard Private Ltd. All rights reserved.
Upgrade To Premium Services
Business Standard is happy to inform you of the launch of "Business Standard Premium Services"
As a premium subscriber you get an across device unfettered access to a range of services which include:
- Access Exclusive content - articles, features & opinion pieces
- Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
- Access to 17 plus years of content archives
- Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
- End of day news alerts on 5 companies (via email)
- NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
In Partnership with
Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.
Team Business Standard